ArticleJournal of the American Society of Nephrology : JASN2005
Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions.
Article in Journal of the American Society of Nephrology : JASN, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01847313 (Phase 3 Study of the Effect of Glucagon-like-peptide 1), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease
Who cites it
26 citing papers in PubMed, 87 citations in OpenAlex.
- Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.American heart journal · 2013Trial
- Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients.Clinical and experimental nephrology · 2011Trial
- Identifying Key Biomarkers Related to Immune Response in the Progression of Diabetic Kidney Disease: Mendelian Randomization Combined With Comprehensive Transcriptomics and Single-Cell Sequencing Analysis.Journal of inflammation research · 2025Article
- Article
- Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.Journal of diabetes investigation · 2023Article
- Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB.The Journal of pathology · 2018Article
- Combination of melatonin and certain drugs for treatment of diabetic nephropathy in streptozotocin-induced diabetes in rats.Diabetology international · 2016Article
- Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.Mediators of inflammation · 2014Article
- Microinflammation in the pathogenesis of diabetic nephropathy.Journal of diabetes investigation · 2013Review
- Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats.British journal of pharmacology · 2012Article
- The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.Human gene therapy · 2012Article
- Methotrexate Increases Skeletal Muscle GLUT4 Expression and Improves Metabolic Control in Experimental Diabetes.Journal of nutrition and metabolism · 2012Article
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.Diabetologia · 2011 · on this mapArticle
- Endothelin, nitric oxide, and reactive oxygen species in diabetic kidney disease.Contributions to nephrology · 2011Review
- Abnormalities in signaling pathways in diabetic nephropathy.Expert review of endocrinology & metabolism · 2010Article
- Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction.Journal of the American Society of Nephrology : JASN · 2010Article
- Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists.Clinical and experimental nephrology · 2009Review
- Extracellular matrix molecules: potential targets in pharmacotherapy.Pharmacological reviews · 2009Review
- [Gene expression analyses of kidney biopsies: the European renal cDNA bank--Kröner-Fresenius biopsy bank].Der Pathologe · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggested the involvement of inflammatory processes in the pathogenesis of diabetic nephropathy. Methotrexate (MTX), a folic acid antagonist, is widely used for the treatment of inflammatory diseases. Recently, it has been shown that treatment with low-dose MTX reduces the cardiovascular mortality in patients with rheumatoid arthritis, suggesting that MTX has anti-atherosclerotic effects via its anti-inflammatory actions. This study was designed to determine the anti-inflammatory effects of this agent on diabetic nephropathy. Diabetes was induced in Sprague-Dawley rats with streptozotocin, and MTX (0.5 or 1.0 mg/kg) was administered once a week for 8 wk. Treatment with MTX reduced urinary albumin excretion, mesangial matrix expansion, macrophage infiltration, expression of TGF-beta and type IV collagen, and intercellular adhesion molecule-1 in glomeruli. MTX also reduced the high glucose-induced NF-kappaB activation in vitro and in vivo. The results indicate that intermittent administration of MTX prevented renal injuries without changes in blood glucose level and BP in experimental diabetic rats. The protective effects of MTX are suggested to be mediated by its anti-inflammatory actions through inhibition of NF-kappaB activation and consequent reduction of intercellular adhesion molecule-1 expression and macrophage infiltration. The results suggest that anti-inflammatory agents might be beneficial for the treatment of diabetic nephropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.